August 10, 2017
The National Law Journal
On August 10, 2017, the Federal Circuit ruled in favor of Finnegan client Eli Lilly and its subsidiary Avid Radiopharmaceuticals, ordering Alzheimer's Institute of America (AIA) to pay nearly $8.5 million in attorneys' fees to Eli Lilly and Avid.
For nearly a decade, AIA filed suit against several university and pharmaceutical researchers, including Avid, alleging infringement on patents covering the research and treatment of Alzheimer's disease. In 2012, Avid argued that AIA never owned the patent and a Pennsylvania district court agreed that AIA did not have standing to assert the patent. The judge also ruled that the evidence showed that AIA's principal conspired with two scientists to hide their blockbuster Alzheimer’s discovery from their university employers. As a result, Avid sought recovery of its attorneys' fees under Section 285 of the Patent Act.
Media Mention
Women in Business Law Americas Awards 2024: Three Finnegan Attorneys Shortlisted
April 7, 2024
Press Release
Finnegan and BMW Group Successfully Demolish Non-Practicing Entity NorthStar’s Efforts
April 3, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.